vs
Side-by-side financial comparison of Opus Genetics, Inc. (IRD) and Satellogic Inc. (SATL). Click either name above to swap in a different company.
Satellogic Inc. is the larger business by last-quarter revenue ($6.2M vs $3.9M, roughly 1.6× Opus Genetics, Inc.).
Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.
Satellogic Inc. is an American company specializing in Earth-observation satellites, founded in 2010 by Emiliano Kargieman and Gerardo Richarte.
IRD vs SATL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $6.2M |
| Net Profit | — | $30.5M |
| Gross Margin | — | — |
| Operating Margin | — | -114.2% |
| Net Margin | — | 488.0% |
| Revenue YoY | -10.2% | — |
| Net Profit YoY | 53.0% | — |
| EPS (diluted) | — | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $6.2M | ||
| Q3 25 | $3.1M | $3.6M | ||
| Q2 25 | $2.9M | $4.4M | ||
| Q1 25 | $4.4M | $3.4M | ||
| Q4 24 | $4.3M | — | ||
| Q3 24 | $3.9M | — | ||
| Q2 24 | $1.1M | $3.5M | ||
| Q1 24 | $1.7M | — |
| Q4 25 | — | $30.5M | ||
| Q3 25 | $-17.5M | $4.0M | ||
| Q2 25 | $-7.4M | $-6.7M | ||
| Q1 25 | $-8.2M | $-32.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-7.5M | — | ||
| Q2 24 | $-7.8M | $-18.1M | ||
| Q1 24 | $-7.1M | — |
| Q4 25 | — | -114.2% | ||
| Q3 25 | -269.9% | -222.5% | ||
| Q2 25 | -309.0% | -141.6% | ||
| Q1 25 | -227.2% | -280.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | -207.1% | — | ||
| Q2 24 | -748.9% | -419.2% | ||
| Q1 24 | -450.5% | — |
| Q4 25 | — | 488.0% | ||
| Q3 25 | -566.9% | 109.2% | ||
| Q2 25 | -257.5% | -149.8% | ||
| Q1 25 | -187.5% | -961.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | -194.6% | — | ||
| Q2 24 | -698.3% | -517.0% | ||
| Q1 24 | -415.3% | — |
| Q4 25 | — | $0.24 | ||
| Q3 25 | $-0.25 | $-0.02 | ||
| Q2 25 | $-0.12 | $-0.06 | ||
| Q1 25 | $-0.24 | $-0.34 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.29 | — | ||
| Q2 24 | $-0.30 | $-0.20 | ||
| Q1 24 | $-0.29 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $45.1M | $94.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.3M | $60.5M |
| Total Assets | $50.2M | $151.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.1M | $94.4M | ||
| Q3 25 | $30.8M | $28.3M | ||
| Q2 25 | $32.4M | $32.6M | ||
| Q1 25 | $41.8M | $17.7M | ||
| Q4 24 | $30.3M | — | ||
| Q3 24 | $36.6M | — | ||
| Q2 24 | $41.4M | $25.6M | ||
| Q1 24 | $47.2M | — |
| Q4 25 | $15.3M | $60.5M | ||
| Q3 25 | $6.0M | $-56.9M | ||
| Q2 25 | $17.5M | $-68.1M | ||
| Q1 25 | $5.1M | $-83.1M | ||
| Q4 24 | $6.7M | — | ||
| Q3 24 | $34.3M | — | ||
| Q2 24 | $40.6M | $19.1M | ||
| Q1 24 | $46.1M | — |
| Q4 25 | $50.2M | $151.3M | ||
| Q3 25 | $36.1M | $70.9M | ||
| Q2 25 | $38.7M | $73.8M | ||
| Q1 25 | $48.2M | $61.4M | ||
| Q4 24 | $36.9M | — | ||
| Q3 24 | $40.4M | — | ||
| Q2 24 | $44.8M | $76.6M | ||
| Q1 24 | $51.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-35.3M | $-9.5M |
| Free Cash FlowOCF − Capex | — | $-12.8M |
| FCF MarginFCF / Revenue | — | -204.9% |
| Capex IntensityCapex / Revenue | — | 53.6% |
| Cash ConversionOCF / Net Profit | — | -0.31× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-34.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-35.3M | $-9.5M | ||
| Q3 25 | $-6.2M | $-8.4M | ||
| Q2 25 | $-10.3M | $-4.3M | ||
| Q1 25 | $-9.0M | $-4.7M | ||
| Q4 24 | $-25.6M | — | ||
| Q3 24 | $-5.1M | — | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $-5.7M | — |
| Q4 25 | — | $-12.8M | ||
| Q3 25 | — | $-9.7M | ||
| Q2 25 | — | $-5.1M | ||
| Q1 25 | — | $-6.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -204.9% | ||
| Q3 25 | — | -267.2% | ||
| Q2 25 | — | -115.3% | ||
| Q1 25 | — | -195.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 53.6% | ||
| Q3 25 | — | 36.8% | ||
| Q2 25 | — | 17.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -0.31× | ||
| Q3 25 | — | -2.11× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IRD
Segment breakdown not available.
SATL
| Transferred At Point In Time | $5.7M | 91% |
| Other | $547.0K | 9% |
